Company file · STE

Steris

Steris' revenue rose 8.7% in FY2026, to $5.9B, and net income rose 27.3% to $782M

Revenue rose 8.7% to $5.9B in FY2026, from $5.5B in FY2025. Net income rose 27.3% to $782M. Healthcare was the largest segment, at 71% of revenue.

Prepared from SEC filings · Latest annual report: 10-K for FY2026 (filed May 29, 2026) · Latest quarter: 10-Q for the quarter ended Sep 30, 2026 (filed Nov 5, 2026) · Data pulled Nov 11, 2026

Key facts

Steris (NYSE: STE) closed fiscal 2026 on Mar 31, 2026 with revenue of $5.9B, up 8.7% from a year before; net income came to $782M, up 27.3%. Its newest quarterly report covers the three months to Sep 30, 2026: revenue of $1.6B, up 8.8% on the same stretch of the prior year, and net income of $214M. Broken down by segment, Healthcare led with 71% of fiscal 2026 revenue. Sources: 10-K for fiscal 2026 (filed May 29, 2026) and 10-Q for the quarter ended Sep 30, 2026 (filed Nov 5, 2026).

Revenue$5.9BFY2026 · +8.7% vs FY2025

Net income$782MFY2026 · +27.3% vs FY2025

Operating cash flow$1.3BFY2026 · +16.8% vs FY2025

Cash & equivalents$531Mat Sep 30, 2026 · +20.8% vs FY2026 end

Total debt$1.9Bat Sep 30, 2026 · −2.0% vs FY2026 end

Diluted shares99MFY2026 avg · −0.4% vs FY2025

Revenue and net income, three fiscal yearsBy fiscal year, $bn

RevenueNet income

Source: 10-K FY2026, filed May 29, 2026

Quarterly revenue: fiscal 2027 vs a year earlierFiscal Q1–Q2, $bn (each quarter from that quarter's 10-Q)

FY2026FY2027

Source: 10-Q filed Aug 7, 2026 · 10-Q filed Nov 5, 2026

How it makes money

By segment, FY2026

LineAmountSharevs FY2025
Healthcare$4.2B71%+8.5%
Applied Sterilization Technologies$1.1B19%+9.6%
Life Science Member$589M10%+8.6%

Source: 10-K FY2026, XBRL breakdown

By segment in FY2026: Healthcare (71%), Applied Sterilization Technologies (19%) and Life Science Member (10%), as shares of total revenue. Total revenue was $5.9B.

By segment: three-year mixShare of the total each fiscal year

FY2024

70%19%11%

FY2025

71%19%10%

FY2026

71%19%10%

HealthcareApplied Sterilization TechnologiesLife Science Member

Source: 10-K FY2026

By product or service, FY2026

Products$3.1B52%+6.6%

Services$2.9B48%+11.1%

Share is of the FY2026 total; the last column is the change from FY2025.

Learn more: Revenue vs. net income · Gross, operating and net margin

What changed last quarter

How the quarter compared with a year earlier

Comparing Q2 FY2027 (Jul to Sep 2026) compared with Q2 FY2026 (Jul to Sep 2025)

Each pair of bars shows the dollar amount for both quarters. Longer bar, more money. Bars in a group share one scale.

Q2 FY2027Q2 FY2026

Company

Revenue

$1.6B Q2 FY2027

$1.5B Q2 FY2026

8.8% increase

Net income

$214M Q2 FY2027

$192M Q2 FY2026

11.4% increase

Source: Steris 10-Q for the quarter ended Sep 30, 2026, filed Nov 5, 2026

By segment

Healthcare

$1.1B Q2 FY2027

$1.0B Q2 FY2026

8.6% increase

Applied Sterilization Technologies

$296M Q2 FY2027

$282M Q2 FY2026

5.0% increase

Source: Steris 10-Q for the quarter ended Sep 30, 2026, filed Nov 5, 2026

Cash & equivalents $531M at Sep 30, 2026, vs $440M at FY2026 end.
Total debt $1.9B at Sep 30, 2026, vs $1.9B at FY2026 end.
Operating cash flow, first 6 months of fiscal 2027: $656M vs $708M a year earlier.

The bull case and the bear case

The bull case

Revenue rose 8.7% in FY2026 to $5.9B, from $5.5B a year earlier. 10-K, FY2026
Net income rose 27.3% in FY2026 to $782M, from $615M. 10-K, FY2026
Operating cash flow rose 16.8% in FY2026 to $1.3B. 10-K, FY2026
Total debt fell 5.5% in FY2026 to $1.9B. 10-K, FY2026

The bear case

The company's own risk factors are in Item 1A of its 10-K. Risks common in this industry include regulation; pricing and reimbursement; competition. 10-K, Item 1A

What optimists and skeptics tend to point to, each tied to a filing. Ticker Sage doesn't pick a side, and neither list is a reason to buy or sell.

What the company does

Steris is in the health care equipment industry, part of the health care sector. The SEC files it under Orthopedic, Prosthetic & Surgical Appliances & Supplies.

Steris reports 3 segments: Healthcare, Applied Sterilization Technologies and Life Science Member.

Its fiscal year ends in March; the latest, FY2026, ended Mar 31, 2026.

Source: 10-K, Item 1 Business

Risks common in this industry

These are general risks for companies in the health care equipment industry. They are not a summary of Steris’s own risk factors; for those, read Item 1A of its latest 10-K, linked below.

RegulationApprovals, safety rules and government oversight shape what it can sell and how.
Pricing and reimbursementPayers, insurers and governments influence what it can charge.
CompetitionNew treatments, generics and rival products can take share.
LitigationProduct liability and other legal claims can lead to costs.
SupplyManufacturing and supplier problems can interrupt products.

Source: 10-K, Item 1A Risk Factors (the company's own list, in the company's words)

Three years of key numbers

Every number links to its filing; hover for the XBRL tag. A dash means the number isn't cleanly available, and we don't estimate it.

US$	FY2024	FY2025	FY2026
Revenue	$5.1B	$5.5B	$5.9B
Net income	$378M	$615M	$782M
Operating cash flow	$973M	$1.1B	$1.3B
Cash & equivalents (year end)	$207M	$172M	$440M
Total debt (year end)	$3.2B	$2.0B	$1.9B
Diluted shares	99M	99M	99M

Revenue: Total revenue for the fiscal year, as the company reports it on its income statement.
Net income: Net income attributable to the company's shareholders, after all costs, interest and taxes.
Operating cash flow: Cash the business brought in from its day-to-day operations during the year (cash flow statement).
Cash & equivalents: Cash and short-term investments that count as cash equivalents on the balance sheet. Excludes longer-dated marketable securities.
Total debt: Short-term and long-term debt combined, at carrying value, as the company totals it.
Diluted shares: Weighted average shares outstanding for the year, including the effect of options and stock awards.

Learn more: How to read an income statement · Earnings per share, basic and diluted · Free cash flow · How to read a balance sheet · Growth rate calculator · P/E calculator · Market cap calculator · Free cash flow calculator · Return on equity and assets calculator

Explainers for this page

Plain-English guides to terms this file uses, with real numbers from filings.

About these numbers

Steris names its fiscal year by the calendar year in which it ends, so FY2026 is the year that ended Mar 31, 2026.

Recent filings

Form	Filed	Period
10-Q	Nov 5, 2026	Sep 30, 2026
10-Q	Aug 7, 2026	Jun 30, 2026
DEF 14A	Jun 11, 2026	Jul 31, 2026
10-K	May 29, 2026	Mar 31, 2026

Learn more: 10-K vs. 10-Q vs. 8-K · Form 4 insider filings · Fiscal years and quarters

Common questions about Steris

How does Steris make money?

Fiscal 2026 revenue: $5.9B. By segment in FY2026: Healthcare (71%), Applied Sterilization Technologies (19%) and Life Science Member (10%), as shares of total revenue. Total revenue was $5.9B. Source: 10-K for fiscal 2026, filed May 29, 2026.

What was Steris's revenue in fiscal 2026?

$5.9B, up 8.7% from fiscal 2025 ($5.5B). The year ended Mar 31, 2026; for fiscal 2024 the figure was $5.1B. Source: 10-K for fiscal 2026, filed May 29, 2026.

Is Steris profitable?

Net income was $782M in fiscal 2026 (up 27.3%; fiscal 2025 was $615M). That counts as a GAAP profit. The latest quarter, ended Sep 30, 2026: net income was $214M. The page's About these numbers section explains what is included. Source: 10-K for fiscal 2026, filed May 29, 2026.

What did Steris report in its latest quarterly filing?

For the three months to Sep 30, 2026: revenue $1.6B (up 8.8% from $1.5B) and net income $214M (up 11.4% from $192M). Source: 10-Q for the quarter ended Sep 30, 2026, filed Nov 5, 2026.

How much cash and debt does Steris have?

As of Sep 30, 2026: $531M of cash and cash equivalents, $1.9B of total debt. Total debt here is short-term and long-term debt combined, at carrying value, as the company totals it. Source: 10-Q filed Nov 5, 2026.

What are the main risks Steris faces?

Steris's own risk factors are in Item 1A of its 10-K for fiscal 2026, filed May 29, 2026. Risks that are common among companies in the health care equipment industry include Regulation; pricing and reimbursement; competition; litigation; supply. The first: Approvals, safety rules and government oversight shape what it can sell and how. Source: 10-K, Item 1A Risk Factors.

Where do these Steris numbers come from?

The 10-K filed May 29, 2026 (fiscal 2026) and the 10-Q filed Nov 5, 2026 (quarter ended Sep 30, 2026), as published in the SEC's XBRL data. Click any number to open the filing it came from. Methodology explains how fiscal years and missing numbers are handled.

Tracked funds that report owning Steris

Citadel Advisors: 404,266 shares, reported value $85.1M at Jun 30, 2026 (+268.0% in shares since the filing for Mar 31, 2026). Form 13F filed Sep 2, 2026.
Millennium Management: 229,133 shares, reported value $48.2M at Jun 30, 2026 (+802.9% in shares since the filing for Mar 31, 2026). Form 13F filed Aug 14, 2026.
Renaissance Technologies: 115,913 shares, reported value $24.4M at Jun 30, 2026 (new in this filing). Form 13F filed Aug 13, 2026.
Two Sigma Investments: 56,707 shares, reported value $11.9M at Jun 30, 2026 (−88.2% in shares since the filing for Mar 31, 2026). Form 13F filed Aug 14, 2026.
Baillie Gifford: 27,785 shares, reported value $5.8M at Sep 30, 2026 (new in this filing). Form 13F filed Nov 9, 2026.
Bridgewater Associates: 9,809 shares, reported value $2.1M at Jun 30, 2026 (−11.9% in shares since the filing for Mar 31, 2026). Form 13F filed Aug 14, 2026.

From each fund’s latest Form 13F, which is filed up to 45 days after quarter end and lists long positions in US-listed stocks only. A listing here is a fact about a filing, not a view on the stock. What a 13F does and doesn’t show.

Disclosures

Editor holdings in STE: The editor holds no position in Steris (STE). As of Nov 11, 2026.
Trading rule: The editor does not buy or sell STE from 3 days before to 3 days after this page is published or substantively updated.
Compensation: Nobody paid for this page. No affiliate links on this page.
Sources: The company's SEC filings, linked next to each number or, for charts, in the source line under them.
Last updated: Nov 10, 2026

General education, the same for every reader. Not a recommendation to buy, sell or hold STE, and it doesn't consider your situation.

Compare with peers

Company	Fiscal year	Revenue	Revenue growth	Net income
SterisSTE	FY2026	$5.9B	+8.7%	$782M
AbbottABT	FY2025	$44.3B	+5.7%	$6.5B
Intuitive SurgicalISRG	FY2025	$10.1B	+20.5%	$2.9B
MedtronicMDT	FY2026	$36.4B	+8.4%	$4.8B
StrykerSYK	FY2025	$25.1B	+11.2%	$3.2B

Each row is that company’s latest fiscal year from its own 10-K, using its own revenue and net income lines. Fiscal years end in different months, and line definitions differ (banks, insurers and oil companies count revenue differently), so this is a rough side-by-side, not a like-for-like comparison.

More company files

New to filings? Learn has plain-English explainers and Tools has calculators. Methodology & Disclosures covers where every number comes from.